{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-139561","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.831248+00:00","generated_at":"2026-06-15T09:47:17.696278+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biote Q1 revenue $44.8M (+20.7%), net loss $21.4M; launches warrant exchange offer","bullets":["Revenue $44.8M (+20.7% YoY); gross margin 69.1% (+220 bps).","Net loss $(21.4)M ($(0.39) per share) vs net income $9.4M in Q1 2022.","Adjusted EBITDA $13.1M (+12.4% YoY); maintains FY 2023 guidance $190-200M revenue, $56-60M adj EBITDA.","Offer: each outstanding warrant exchanged for 0.23 common shares; consent to convert remaining at 0.207.","Parties representing 19.4% of public warrants and 59.3% of private warrants have agreed to tender."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-139561","json":"https://secwatch.observer/filing/0001193125-23-139561.json","markdown":"https://secwatch.observer/filing/0001193125-23-139561.md","text":"https://secwatch.observer/filing/0001193125-23-139561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/0001193125-23-139561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/d474476d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:47:17.696278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d1cffd2bd3060508e36ed975e13eea67739f6a9","claim":"biote Corp. reported first quarter ended March 31, 2023 results: revenue $44.8 million, net income $(21.4) million, EPS $(0.39) per share. Guidance reaffirmed.","evidence_excerpt":"hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights, year-over-year: • Revenue of $44.8 million, a 20.7% increase • Gross profit margin of 69.1%, a 220-basis point increase • Net loss of $(21.4) million and GAAP loss per share of $(0.39), primarily reflecting the impact","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/0001193125-23-139561-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$44.8 million"},{"label":"Net income","value":"$(21.4) million"},{"label":"EPS","value":"$(0.39) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}